12.11
+6.70%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Intellia Therapeutics
From its filings with the US Securities and Exchange Commission
Intellia Therapeutics is based in Cambridge, Massachusetts and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker NTLA. The SEC classifies its business as in vitro & in vivo diagnostic substances. In the fiscal year to 31 December 2025, it reported revenue of $67.7m and a net loss of $412.7m. At that date it held total assets of $842.1m and shareholders' equity of $671.4m.
Intellia Therapeutics, Inc. (“we,” “us,” “our,” “Intellia,” or the “Company”) is a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. Our mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, we aim to reset the standard for medicine by durably treating the root causes of disease.
For over a decade, Intellia has applied its proprietary technologies and expertise, including CRISPR-based gene editing technologies, oligonucleotides, and lipid nanoparticles (“LNPs”), to develop novel, first-in-class product candidates. This includes the development of lonvoguran ziclumeran (“lonvo-z,” also referred to as NTLA-2002) for the treatment of hereditary angioedema (“HAE”) and nexiguran ziclumeran (“nex-z,” also referred to as NTLA-2001) for the treatment of transthyretin (“ATTR”) amyloidosis. These lead product candidates are the first in vivo genome editing product candidates into Phase 3 development. These systemically administered CRISPR-based candidates are designed to address diseases with high unmet need with a single intravenous (“IV”) infusion that is administered in an outpatient setting. Lonvo-z and nex-z are currently in Phase 3 clinical development, and we are preparing for the planned commercial launch of lonvo-z in the first half of 2027.
Quoted from its 10-K, filed 26 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 6 May 2016
- Employees
- 377
- Website
- intelliatx.com ↗
- Head office
- 400 TECHNOLOGY SQUARE, CAMBRIDGE, MA
- Incorporated in
- DE
- Classification
- In Vitro & In Vivo Diagnostic Substances
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Dr. Frank VerwielIndependent Chairman of the Board$499,927
- Dr. John LeonardPresident, Chief Executive Officer, Director, since 2014$15.3m
- Mr. Edward DulacChief Financial Officer, Executive Vice President, Treasurer$6.7m
- Ms. Eliana ClarkExecutive Vice President, Chief Technology Officer
- Dr. Birgit SchultesExecutive Vice President, Chief Scientific Officer
- Mr. James BastaExecutive Vice President, General Counsel, Corporate Secretary$4.9m
- Dr. David LebwohlExecutive Vice President, Chief Medical Officer$5.6m
- Mr. Michael DubeChief Accounting Officer, Vice President$1.3m
- Ms. Muna BhanjiIndependent Director$467,659
- Mr. William ChaseIndependent Director$479,927
- Dr. Frederick CohenIndependent Director$457,878
- Mr. Brian GoffIndependent Director$828,745
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 54
- Environment
- 29
- Social
- 68
- Governance
- 64
- Women in the workforce
- 54%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Intellia Therapeutics Inc has a strong intellectual property portfolio consisting of patents and licenses, providing them with a competitive advantage in gene editing technologies.
- The company has a diverse pipeline of potential therapeutics, covering various diseases and conditions, which helps in reducing dependency on single product success.
- Intellia Therapeutics has formed strategic partnerships and collaborations with leading pharmaceutical companies, allowing them to benefit from shared resources, expertise, and strong distribution networks.
Weaknesses
- Being a relatively small biotechnology company, Intellia Therapeutics Inc may face financial limitations and struggle to compete against larger, well-established competitors in terms of resources and market presence.
- The company's success heavily relies on the successful development and approval of its pipeline products. Any setbacks or delays in clinical trials or regulatory processes could negatively impact the company.
- As a gene editing company, Intellia Therapeutics is subject to ethical and regulatory concerns surrounding the use of gene therapies, which can limit market adoption and public acceptance.
Opportunities
- The increasing prevalence of genetic disorders and chronic diseases presents a significant opportunity for Intellia Therapeutics to develop and commercialize innovative gene therapies that can address unmet medical needs.
- Advancements in gene editing technologies and the growing understanding of genetic mechanisms provide Intellia Therapeutics with the opportunity to enhance the efficacy and safety of their therapies, potentially leading to greater market adoption.
- Expanding into emerging markets and forming partnerships with international pharmaceutical companies can facilitate global market penetration for Intellia Therapeutics and increase their revenue streams.
Threats
- Intense competition within the gene editing industry poses a threat to Intellia Therapeutics' market share and profitability, as larger players with more resources may develop similar or superior therapies.
- Regulatory hurdles and evolving government policies related to gene editing and healthcare reimbursement can impact the speed of product approvals and the pricing and reimbursement of Intellia Therapeutics' therapies.
- Unforeseen adverse events, such as unexpected side effects or lack of long-term safety data, in Intellia Therapeutics' clinical trials or approved products can lead to reputational damage and loss of investor confidence.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.